on-randomized clinical trial to compare the immunogenicity of revaccination with 23-valent pneumococcal polysaccharide vaccine between healthy elderly and those with diabetes in Korea

MSD Korea0 个研究点目标入组 254 人开始时间: 待定最近更新: 2020年7月13日

适应症

试验速览

暂无简介。

•? subjects aged 70-75 years who received PPSV23 in previous 5-7 years, Subjects who after hearing and fully understanding the details of this clinical trial, voluntarily decides to participate and agrees in writing to comply, who is determined to be appropriate to participate in this clinical trial through self-disease, physical examination, and researcher's clinical judgment that can be visited and traced to all predetermined schedules of this clinical trial.

•Those who have been identified for pneumococcal infection in the past 5 years, those who have been treated with anti-cancer therapy for malignant tumors within the past 30 days, those who have received high doses of systemic steroids within the past 30 days (Prednisolone>0.5 mg/kg/day ), those who have received a blood product within the past 6 months, patients with significant acute or chronic infections within the past 7 days, or those who have had a fever in the previous day, who have a serious chronic or progressive disease, for medical reasons or other reasons, therefore, the investigator is determined to be unsuitable for participation in the clinical trial.

发起方

MSD Korea